Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MART-1 TCR retroviral vector-transduced autologous TIL

Human tumor infiltrating lymphocytes (TIL) isolated from a melanoma patient and were engineered to react with the melanoma antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A). These TILs are transfected with a retroviral vector encoding anti-MART-1 specific T-cell receptors, grown in culture, and then transferred back to the patient. These genetically modified TIL may recognize and halt the growth of MART-1-expressing melanoma cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	MSGV1AIB (anti-MART-1 TCR) retroviral vector-transduced autologous TIL
Code name:	DMF5

anti-MART-1 TCR retroviral vector-transduced autologous TIL

Search NCI's Drug Dictionary